GE Healthcare announced that the preliminary results of two Phase 3 studies for [18F]flutemetamol, a PET imaging agent for detection of beta amyloid, met their primary endpoints.
One study, in terminally ill patients who agreed to undergo brain autopsy, showed strong concordance between flutemetamol PET images and Alzheimer’s disease-associated beta amyloid brain pathology. The other study, in young healthy volunteers aged <40 years, had results concordant with the known lack of brain amyloid in this population. Full results of these studies will be presented in the coming months.
[18F]flutemetamol is being studied to determine its ability to detect amyloid deposition for a more accurate assessment of patients with suspected Alzheimer’s disease and other cognitive disorders.
For more information visit www.gehealthcare.com.